WO2020217116A3 - Long acting inhalation compositions of indacaterol - Google Patents

Long acting inhalation compositions of indacaterol Download PDF

Info

Publication number
WO2020217116A3
WO2020217116A3 PCT/IB2020/052975 IB2020052975W WO2020217116A3 WO 2020217116 A3 WO2020217116 A3 WO 2020217116A3 IB 2020052975 W IB2020052975 W IB 2020052975W WO 2020217116 A3 WO2020217116 A3 WO 2020217116A3
Authority
WO
WIPO (PCT)
Prior art keywords
indacaterol
long acting
inhalation compositions
acting inhalation
mcg
Prior art date
Application number
PCT/IB2020/052975
Other languages
French (fr)
Other versions
WO2020217116A2 (en
Inventor
Hiren Patel
Bikash Kumar Sahoo
Sanjay Saha
Original Assignee
Orbicular Pharmaceutical Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbicular Pharmaceutical Technologies Pvt Ltd filed Critical Orbicular Pharmaceutical Technologies Pvt Ltd
Publication of WO2020217116A2 publication Critical patent/WO2020217116A2/en
Publication of WO2020217116A3 publication Critical patent/WO2020217116A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable long acting inhalation composition comprising indacaterol or its acceptable salts at a concentration from about 15 mcg/mL up to about 150 mcg/mL, and optionally comprising one or more anticholinergic agent. It also relates to use of such compositions for the prevention and/or treatment of respiratory, inflammatory or chronic obstructive airway disease (CORD).
PCT/IB2020/052975 2019-03-28 2020-03-28 Long acting inhalation compositions of indacaterol WO2020217116A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941012201 2019-03-28
IN201941012201 2019-03-28

Publications (2)

Publication Number Publication Date
WO2020217116A2 WO2020217116A2 (en) 2020-10-29
WO2020217116A3 true WO2020217116A3 (en) 2020-12-03

Family

ID=72940917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/052975 WO2020217116A2 (en) 2019-03-28 2020-03-28 Long acting inhalation compositions of indacaterol

Country Status (1)

Country Link
WO (1) WO2020217116A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200375945A1 (en) * 2019-06-03 2020-12-03 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
WO2021262648A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol and budesonide
CN115475165B (en) * 2021-05-31 2024-03-08 中国科学院上海药物研究所 Application of indacaterol maleate in hemorrhagic brain injury related diseases
CN117679423A (en) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 Inhalation pharmaceutical composition for preventing or treating respiratory diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110770A2 (en) * 2011-02-17 2012-08-23 Cipla Limited Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110770A2 (en) * 2011-02-17 2012-08-23 Cipla Limited Pharmaceutical composition

Also Published As

Publication number Publication date
WO2020217116A2 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
WO2020217116A3 (en) Long acting inhalation compositions of indacaterol
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
MY174002A (en) Combination theraphy for the treatment of diabetes
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
EP1938814A4 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
MX2010001236A (en) 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators.
UA88941C2 (en) Substituted 4-phenyltetrahydroisoquinolines, their use as drug, and drug containing them
EA201401354A1 (en) NEW DOSED FORM AND PREPARATION CONTAINING ABEDTEROL
HK1074582A1 (en) Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
MX2018014425A (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof.
MX2022006333A (en) Tri-heterocyclic compound as jak inhibitor, and use thereof.
EP4400119A3 (en) Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
MX2023013683A (en) Fused isoxazolyl compounds as kat6a inhibitors.
IL168308A (en) Compositions containing roflumilast and formoterol
MXPA05010160A (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
MX2021003508A (en) 5-azaindazole derivatives as adenosine receptor antagonists.
MX2009006692A (en) Prostacyclin derivatives.
MX2023011546A (en) Nasal compositions comprising alcaftadine.
MXPA05010161A (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.
MX2022007175A (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α<sub>1</sub>-ANTIT RYPSIN DEFICIENCY.
MX2020010977A (en) Methods of treating fungal infections.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20794770

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20794770

Country of ref document: EP

Kind code of ref document: A2